mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic

被引：7

作者：

Chen, Peixian ^{[1
]}

Shi, Xiaoye ^{[1
]}

He, Weixin ^{[2
]}

Zhong, Guowei ^{[3
]}

Tang, Yan ^{[1
]}

Wang, Hailin ^{[4
]}

Zhang, Peidong ^{[5
]}

机构：

[1] Southern Med Univ, Sch Clin Med 2, Zhujiang Hosp, Guangzhou, Guangdong, Peoples R China

[2] Southern Med Univ, Sch Clin Med 1, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China

[3] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China

[4] Peoples Hosp Guangning Cty, Heart Ctr, Dept Cardiol, 18 Renmin Rd, Zhaoqing City 526300, Guangdong, Peoples R China

[5] Southern Med Univ, Zhujiang Hosp, Heart Ctr, Dept Cardiol, Guangzhou, Guangdong, Peoples R China

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2022年 / 18卷 / 01期

关键词：

COVID-19; mRNA vaccines; infectious diseases; immune responses; clinical trial; SARS-CoV-2; UNITED-STATES; BNT162B2; IMMUNOGENICITY; MYOCARDITIS; VECTOR; SAFETY; 1ST;

D O I：

10.1080/21645515.2022.2040330

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

As an acute respiratory infectious disease, COVID-19 threatens the safety of global public health. Given the current lack of specific treatment against this disease, research and development of vaccines have become sharp weapons for overcoming the pandemic. mRNA vaccines have become the lead in COVID-19 vaccination strategies due to their advantages, such as rapid industrial production and efficacy. A total of 137 COVID-19 vaccines have entered the clinical trial stage, among which 23 are mRNA vaccines, accounting for 17% of the total vaccines. Herein, we summarize the research and developmental processes of mRNA vaccines as well as the approach for protecting the human body against infection. Focusing on the latest clinical trial data of two COVID-19 mRNA vaccines from Pfizer and Modena, we discuss their effectiveness and safety. Finally, we analyze the challenges and problems that mRNA vaccines face in controlling the COVID-19 pandemic.

引用

页数：13

共 110 条

[1] mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
A Feldman, Robert
Fuhr, Rainard
Smolenov, Igor
Ribeiro, Amilcar
Panther, Lori
Watson, Mike
Senn, Joseph J.
Smith, Mike
Almarsson, Orn
Pujar, Hari S.
Laska, Michael E.
Thompson, James
Zaks, Tal
Ciaramella, Giuseppe
[J]. VACCINE, 2019, 37 (25) : 3326 - 3334
[2] Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Abu-Raddad, Laith J.
Chemaitelly, Hiam
Butt, Adeel A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) : 187 - 189
[3] Aleem A., 2022, STATPEARLS
[4] Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
Ali, Kashif
Berman, Gary
Zhou, Honghong
Deng, Weiping
Faughnan, Veronica
Coronado-Voges, Maria
Ding, Baoyu
Dooley, Jacqueline
Girard, Bethany
Hillebrand, William
Pajon, Rolando
Miller, Jacqueline M.
Leav, Brett
McPhee, Roderick
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24) : 2241 - 2251
[5] Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study
Almufty, Hind B.
Mohammed, Shinah A.
Abdullah, Arshad M.
Merza, Muayad A.
[J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (05)
[6] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J.
Rouphael, N. G.
Widge, A. T.
Jackson, L. A.
Roberts, P. C.
Makhene, M.
Chappell, J. D.
Denison, M. R.
Stevens, L. J.
Pruijssers, A. J.
McDermott, A. B.
Flach, B.
Lin, B. C.
Doria-Rose, N. A.
O'Dell, S.
Schmidt, S. D.
Corbett, K. S.
Swanson, P. A., II
Padilla, M.
Neuzil, K. M.
Bennett, H.
Leav, B.
Makowski, M.
Albert, J.
Cross, K.
Edara, V. V.
Floyd, K.
Suthar, M. S.
Martinez, D. R.
Baric, R.
Buchanan, W.
Luke, C. J.
Phadke, V. K.
Rostad, C. A.
Ledgerwood, J. E.
Graham, B. S.
Beigel, J. H.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) : 2427 - 2438
[7] SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine
Anderson, Mark
Stec, Michael
Rewane, Ayesan
Landay, Alan
Cloherty, Gavin
Moy, James
[J]. JAMA NETWORK OPEN, 2021, 4 (08)
[8] Association Between Statewide School Closure and COVID-19 Incidence and Mortality in the US
Auger, Katherine A.
Shah, Samir S.
Richardson, Troy
Hartley, David
Hall, Matthew
Warniment, Amanda
Timmons, Kristen
Bosse, Dianna
Ferris, Sarah A.
Brady, Patrick W.
Schondelmeyer, Amanda C.
Thomson, Joanna E.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (09): : 859 - 870
[9] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, Lindsey R.
El Sahly, Hana M.
Essink, Brandon
Kotloff, Karen
Frey, Sharon
Novak, Rick
Diemert, David
Spector, Stephen A.
Rouphael, Nadine
Creech, C. Buddy
McGettigan, John
Khetan, Shishir
Segall, Nathan
Solis, Joel
Brosz, Adam
Fierro, Carlos
Schwartz, Howard
Neuzil, Kathleen
Corey, Larry
Gilbert, Peter
Janes, Holly
Follmann, Dean
Marovich, Mary
Mascola, John
Polakowski, Laura
Ledgerwood, Julie
Graham, Barney S.
Bennett, Hamilton
Pajon, Rolando
Knightly, Conor
Leav, Brett
Deng, Weiping
Zhou, Honghong
Han, Shu
Ivarsson, Melanie
Miller, Jacqueline
Zaks, Tal
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416
[10] Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Bahl, Kapil
Senn, Joe J.
Yuzhakov, Olga
Bulychev, Alex
Brito, Luis A.
Hassett, Kimberly J.
Laska, Michael E.
Smith, Mike
Almarsson, Orn
Thompson, James
Ribeiro, Amilcar
Watson, Mike
Zaks, Tal
Ciaramella, Giuseppe
[J]. MOLECULAR THERAPY, 2017, 25 (06) : 1316 - 1327

← 1 2 3 4 5 6 7 8 9 10 →